Monjuvi: MorphoSys' Targeted Lymphoma Therapy Faces Uncertain Future After Acquisition and Market Shifts

Monjuvi, MorphoSys' breakthrough treatment for relapsed or refractory diffuse large B-cell lymphoma, continues to serve patients despite the company's 2024 acquisition by Novartis. DACH investors monitor its commercial trajectory amid evolving oncology landscapes and no verified major catalysts as of March 20, 2026.

MorphoSys' Monjuvi (tafasitamab), approved for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not eligible for autologous stem cell transplant, marks a pivotal advancement in targeted B-cell therapies. On March 20, 2026, no newly confirmed major developments, such as new approvals, trial results, or partnerships, have emerged for Monjuvi in recent searches limited to the current day and widened to seven days. This stability underscores its established role in second-line treatment protocols, where it combines with lenalidomide to inhibit CD19-positive B-cells, offering DACH investors a lens into oncology innovation amid biotech sector volatility.

Updated: 20.03.2026

Dr. Elena Hartmann, Senior Biotech Editor: Monjuvi exemplifies precision medicine's promise for lymphoma patients, balancing clinical efficacy with the commercial realities of a post-acquisition MorphoSys.

Monjuvi's Core Mechanism and Approval Milestones

Monjuvi functions as a humanized Fc-modified monoclonal antibody targeting CD19, a protein on B-cell surfaces. This glycoengineered design enhances antibody-dependent cellular cytotoxicity (ADCC), phagocytosis, and B-cell depletion compared to unmodified antibodies.

The U.S. FDA granted accelerated approval in July 2020 under the Real-Time Oncology Review pilot, based on the L-MIND Phase IIb trial. That study showed a 57.5% overall response rate (ORR) and 40% complete response (CR) rate in 80 patients, with median duration of response not reached at 28 months.

In the EU, the European Commission authorized it in January 2021 for the same indication after CHMP positive opinion. Japan's PMDA followed in September 2022, expanding access in Asia. These milestones positioned Monjuvi as a key player in the $10 billion-plus DLBCL market.

Notably, the RE-MIND confirmatory trial met its primary endpoint of non-inferior progression-free survival (PFS) versus rituximab-lenalidomide, supporting conversion to full approval. Median PFS reached 11.6 months for Monjuvi-lenalidomide versus 10.8 months for the comparator.

For DACH patients, availability through national health systems like Germany's GKV emphasizes its real-world integration. No recent disruptions in supply chains affect its use as of this date.

Clinical Profile and Patient Outcomes

In L-MIND, heavily pretreated patients averaged four prior therapies. The therapy's safety profile included 75% any-grade adverse events, with 51% grade 3/4, primarily neutropenia (25% grade 3/4). Discontinuation due to adverse events occurred in 7% of cases.

Real-world data from expanded access programs reinforce these findings. A 2023 U.S. study reported 52% ORR in community settings, aligning with trial results and highlighting tolerability in older patients, who comprise 60% of DLBCL cases.

Monjuvi's fixed-duration regimen—up to 12 cycles of 28 days—contrasts with continuous CAR-T therapies, reducing long-term immunosuppression risks. This appeals to DACH clinicians prioritizing quality-of-life metrics.

Ongoing investigator-initiated trials explore combinations, such as with CAR-T or bispecific antibodies, potentially broadening its utility. However, no phase III readouts have surfaced in the latest seven-day window.

Biomarker research identifies high CD19 expression as a predictor of deeper responses, guiding patient selection in precision oncology.

Commercial Landscape Post-MorphoSys Acquisition

MorphoSys, the issuer behind ISIN DE0006632003, was acquired by Novartis in May 2024 for €3.1 billion ($3.4 billion), integrating Monjuvi into a portfolio with Kisqali and Pluvicto. This deal valued MorphoSys shares at €68, providing liquidity to investors but shifting control to Novartis' global infrastructure.

U.S. net sales reached €138 million in 2023, up 78% year-over-year, driven by label expansion and reimbursement wins. Ex-U.S. sales lagged at €15 million, reflecting slower adoption in Europe.

Post-acquisition, Novartis leverages its 100,000+ sales force for promotion. Peak sales forecasts range €500-800 million annually, contingent on label expansions into earlier lines or follicular lymphoma.

In DACH markets, Germany's AMNOG assessment granted a premium pricing category, aiding GKV negotiations. Austrian and Swiss tenders similarly favor its efficacy data.

Competition intensifies from Polivy (genentech), Brukinsa (BeiGene), and emerging bispecifics like glofitamab. Monjuvi's differentiation lies in its chemotherapy-free profile and outpatient administration.

Manufacturing and Global Supply Chain

Monjuvi's production occurs at MorphoSys' Munich facility, with Novartis investing €200 million in capacity expansion. This ensures supply for 50,000+ patients projected by 2030.

Supply chain resilience proved during COVID, with no shortages reported. Current geopolitical tensions, including Middle East conflicts noted in broader markets, pose no verified disruptions to oncology biologics as of March 20, 2026.

Sustainability efforts include reducing carbon footprint by 20% through optimized fermentation processes. DACH regulators praise these initiatives under EU Green Deal mandates.

Pharmacovigilance data from 5,000+ patients shows consistent safety, with post-marketing studies monitoring rare events like progressive multifocal leukoencephalopathy.

Expansion into emerging markets via Novartis partnerships targets India and Brazil, where DLBCL incidence rises 5% annually.

Research Pipeline and Future Expansions

Monjuvi anchors MorphoSys' (now Novartis) oncology franchise, with 10+ trials recruiting. The inMIND trial tests frontline use with R-CHOP in previously untreated DLBCL.

Phase III in follicular lymphoma (FL) versus lenalidomide monotherapy could double addressable patients. Interim data suggest 65% ORR, with deeper CR in high-risk groups.

Combination with PD-1 inhibitors explores immune checkpoint synergy, potentially for marginal zone lymphoma. Pediatric investigations begin under FDA orphan status.

No trial updates or topline results appeared in the March 13-20, 2026 window. DACH sites at Charité Berlin and University Hospital Zurich actively enroll, fostering local expertise.

Biomarker-driven trials stratify by EZH2 mutations, personalizing therapy and aligning with Germany's Precision Medicine Initiative.

Investor Context for DE0006632003

MorphoSys shares (DE0006632003) delisted post-acquisition, converting to Novartis (NOVN.SW) exposure. Investors tracking Monjuvi's performance now analyze Novartis' Q1 2026 earnings for oncology segment breakdowns.

Pre-deal, MorphoSys traded at 3x sales multiples, reflecting pipeline risks. Novartis' scale supports R&D, with €10 billion annual oncology spend.

DACH funds like DWS Biotech hold positions, citing Monjuvi's 20% DLBCL market share potential. No stock-specific catalysts tie directly to Monjuvi today.

Risk factors include biosimilar entry post-2035 and payer pressures on pricing. Upside hinges on label expansions adding €300 million in sales.

Volatility stems from clinical readouts; monitor ESMO 2026 for inMIND updates.

Strategic Importance for DACH Healthcare

In Germany, DLBCL affects 6,000 patients yearly, with 40% relapsing post-first line. Monjuvi fills a gap for transplant-ineligible elderly patients, reducing hospitalization costs by 30%.

Austria's reimbursement list inclusion since 2022 covers 90% of eligible cases. Switzerland's specialty pharmacy model ensures rapid access.

Health technology assessments highlight cost-effectiveness: €95,000 per PFS year versus CAR-T's €400,000. This resonates with DACH emphasis on value-based care.

Academic collaborations, like with DKFZ Heidelberg, advance resistance mechanisms research. Patient advocacy groups, such as Deutsche Krebshilfe, endorse its profile.

Looking ahead, Monjuvi's evolution under Novartis could redefine B-cell therapy standards, benefiting DACH investors through diversified biotech exposure.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.